Onderneming DiaMedica Therapeutics Inc.
Aandelen
DMAC
CA25253X2077
Biotechnologie & Medisch Onderzoek
Geschatte realtime
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
3,07 USD | +2,33% | +22,01% | +11,27% |
Vakgebied
Aantal werknemers: 19
Managers
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Rick Pauls
CEO | Chief Executive Officer | 52 | 01-04-05 |
Scott Kellen
DFI | Director of Finance/CFO | 59 | 01-04-18 |
Ambarish Shah
CTO | Chief Tech/Sci/R&D Officer | - | 01-05-23 |
Chief Tech/Sci/R&D Officer | 62 | 22/01 | |
James Parsons
BRD | Director/Board Member | 58 | 20-10-10 |
Paul Papi
IRO | Public Communications Contact | - | 01-12-16 |
Corporate Officer/Principal | - | - | |
Dominic Cundari
PRN | Corporate Officer/Principal | - | 01-02-22 |
David Wambeke
PRN | Corporate Officer/Principal | - | 11-04-23 |
Besturend
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Richard Kuntz
BRD | Director/Board Member | 66 | 30-05-23 |
Tanya Lewis
BRD | Director/Board Member | 53 | 01-03-23 |
James Parsons
BRD | Director/Board Member | 58 | 20-10-10 |
Michael Giuffre
BRD | Director/Board Member | 68 | 10-08-10 |
Rick Pauls
CEO | Chief Executive Officer | 52 | 01-04-05 |
Richard Pilnik
CHM | Chairman | 67 | 01-05-09 |
Charles Semba
BRD | Director/Board Member | 64 | 15-07-21 |
Aandelenklasse
Stemming | Aantal | Vrij verhandelbaar | Bedrijfseigen aandelen | Drijvend Totaal | |
---|---|---|---|---|---|
Aandeel A | 1 | 37 958 000 | 23 517 237 ( 61,96 %) | 0 | 61,96 % |
Bedrijfsgegevens
DiaMedica Therapeutics, Inc.
301 Carlson Parkway Suite 210
55305, Minneapolis
+
http://www.diamedica.comSector
Herzieningen van WPA
Vaira. 1 jan. | Kapi. | |
---|---|---|
+11,27% | 114 mln. | |
+8,65% | 105 mld. | |
-0,69% | 104 mld. | |
+5,56% | 22,94 mld. | |
-12,31% | 22,34 mld. | |
-5,99% | 19,25 mld. | |
-39,98% | 17,08 mld. | |
-9,26% | 16,96 mld. | |
+7,86% | 14,16 mld. | |
+39,82% | 12,63 mld. |
- Beurs
- Aandelen
- Koers DMAC
- Onderneming DiaMedica Therapeutics Inc.